Skip to main content
Search
Main content
Nature aging
Published

Comparing plasma p-tau217 and plasma p-tau217/Aβ<sub>42</sub> with CSF biomarkers for assessing Alzheimer's disease pathology

Authors

Noëlle Warmenhoven, Alexa Pichet Binette, Lyduine E Collij, Shorena Janelidze, Niklas Mattsson-Carlgren, Pontus Tideman, Ruben Smith, Olof Strandberg, Nicholas J Ashton, Henrik Zetterberg, Alzheimer’s Disease Neuroimaging Initiative, Erik Stomrud, Gemma Salvadó, Oskar Hansson, Sebastian Palmqvist

Abstract

Nat Aging. 2026 Nov 18. doi: 10.1038/s43587-026-01259-z. Online ahead of print.

ABSTRACT

Plasma biomarkers for Alzheimer's disease (AD) on fully automated platforms offer accessible, cost-effective diagnostic tools. Here we aimed to compare Lumipulse plasma phospho-tau217 (p-tau217) and the p-tau217/beta-amyloid42 ratio (p-tau217/Aβ42) with regulatory-authorized cerebrospinal fluid (CSF) biomarkers (Aβ42/Aβ40 and p-tau181/Aβ42) for identifying AD pathology (Aβ-PET visual read) across a memory clinic (n = 129), a primary care (n = 220) and a research cohort (n = 165). Regulatory-authorized cutoffs were used for the plasma and CSF biomarkers. Plasma biomarkers identified Aβ pathology with areas under the curve between 0.90 and 0.96. Using one cutoff, plasma p-tau217 (83-91%) and p-tau217/Aβ42 (83-92%) had comparable accuracies to CSF (88-90%) across all cohorts (all P ≥ 0.05). With a two-cutoff approach, plasma p-tau217 (90-97%) remained comparable to CSF (91%) in the clinical cohorts (all Padj ≥ 0.12). Results with cohort-derived cutoffs are also provided. In conclusion, regulatory-authorized plasma p-tau217 and p-tau217/Aβ42 demonstrated performance comparable to regulatory-authorized CSF tests for detecting Aβ pathology in symptomatic individuals.

PMID:43052398 | DOI:10.1038/s43587-026-01259-z

UK DRI Authors

Prof Henrik Zetterberg

Group Leader

Pioneering the development of fluid biomarkers for dementia

Prof Henrik Zetterberg